BCAB - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the BioAtla First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Bruce Mackle, with LifeSci Advisors. Thank you, Bruce.

You may begin.

Bruce Mackle

good and operator, you, afternoon, everyone. Thank today me on the Dr. are BioAtla from phone With CEO Dr. and Chairman, Short, Jay Co-Founder; Eric Sievers, Chief Officer; and Medical Officer; Sheri Waldron, Financial Lydick, Chief Officer. Richard Chief Commercial

short on results and corporate press business the participate team March Following quarter the release the presentation a afternoon, copy XX, today's financial in and XXXX. update call, A a company's released website. BioAtla Q&A. Earlier first will available ended for are this that of

expectations SEC, cash XX-Q. meetings the uncertainties materially Form actual and and potential and the to risks, about and operations; regarding results filings equivalents statements sufficiency its R&D most progress and for collaborations regarding made and statements like strategic regarding to and and of regulatory trials, include candidates; and and I'd we and its the plans will trials; assets, on that subject the clinical partnerships of plans trials call to product recent but report are remind cash assumptions Before other support and clinical achievements regulatory plans clinical burn. approval trials path the including its its These in regulatory this to with and will during development that fund dosing selected enrollment everyone to forward-looking research with various made differ not begin, conference limited BioAtla's respect results, clinical prospects submissions; are to including, statements, quarterly its cash and can cause programs registration, to, data form described whether expectations for statements timing expectations conduct in of milestones expenses updates, future expectations business

to and which law. information, as Short. reliance to disclaims to over to like on future BioAtla turn reflect statements that, Jay May not speak any events XXXX, XX, place With statements, except Jay? required or cautioned are as by to the obligation such of call You update today, only I'd forward-looking these undue circumstances,

Jay Short

our Thank thanks XXXX you, and BioAtla earnings Bruce, to for for call. joining first quarter us everyone

will related Additional of updated details are share available website. our company today's press today and to what available our presentation, on both we which release are in

all programs. make ongoing to considerable our of clinical progress continue across We

are our readouts treatment prior X of and cancer refractory recent We share of to our median patients treatment. pleased CAB-RORX-ADC data and had for encouraging head a highly who neck lines

control these illustrated patients XX% and in rapid overall with settings. As findings slide best control, deep observed many of the responding. used corporate patients of our support in believe response rate, tumor we XX% disease earlier-line Having presentation, an achieved

In addition, in view safety of therapies. profile, promise this considerable combination future the manageable holds for

year of this observed plan and intense the encouraging we clinical CAB-RORX-ADC, of less data more in to intensive especially dose the on melanoma. of for We dosing and using multiple CAB-RORX-ADC a potentially FDA second benefit QXW Given guidance our with we registrational trial. half XQXW meet strength regimen, the the the with obtained at the responses

melanoma and that more CAB-RORX-ADC in indications, triple-negative where I Phase regimen bar. However, other We not we our study. observed believe, internal we our has in meet cancer, at our tumor do including breast the intensive reduction though, earlier potential did

to prioritization, our more plan regimen to ongoing do explore this at not the due intensive However, time. we

Phase ongoing with our CTLA-X cover I/O CAB will I antibody. Next, I/II trial our

safety responses observed first the to and than our since expanded multiple of treated doubled Our due we results, more higher number progressing was with study, disclosure a late the encouraging which We've dose Phase in at combination I have XXX-milligram well. dose last PD-X. is to data the year, patients

adverse binding as consistent events echoes which observed study anticipated conditional with of very immune-related to ongoing pleased our are our is benefits few the to report our that report, We been II have Phase earlier technology. date,

now treating hold In we per patients flat addition, or the the XXX-milligram at kilogram. are that observed dose XX-milligram also to safety continues approximately profile

dose unprecedented the which on the maximum track a quarter. clear CTLA-X period inhibitor the activity the later for observation safety high not approach remain also in DLT achieved with the to We The has previously this tumor, allows to this been manageable dose clinic. X-gram us at in

for portion completed pleomorphic dosing CAB-AXL-ADC, patients in trial April. As in sarcoma our our in we registrational potentially first the of undifferentiated

to this ADC AXL of also cancer quarter. We later evaluate the remain track patients target agnostic on benefit in clinical

bispecific engager the cab the half. for escalation remains with track Finally, first dose Phase T-cell second on our readout I trial EpCAM in dual CDX

on the now to for second with are obtain registrational we readouts CTLA-X year. reports on in half potentially finalizing or and trials second assets RORX As the and into for this X XXXX, of guidance focused our data are meetings FDA we of quarter more the

In are partners advancing with development on market selected and accelerate clinical our preclinical potential. to addition, we pharmaceutical assets potential their and discussions their maximize both

I and CTLA-X the details will turn will now our insights on RORX call Eric? assets. Eric, to provide and over who additional

Eric Sievers

of required now were responses responses follow-up Notably, are a dosing. Further for received as were who bozoriftimab, response had median cycles, prior response X our X and we third-line [ who target-agnostic date. ] X be second Jay. vedotin patients and of of treatment. intensive confirmed prior XX Among Beginning occurred regimens, evaluable a treatment indication, a XX received who you, the provide CAB-RORX-ADC, head reliable patients to XX X documented, received confirmed and week X in XX to enrolled more the lines will in the X and cancer XX of Thank with dosing X ADC or the to responses therapy. every total day X-week of neck have in estimate X assessment, other from ranging duration.

from observed biopsies target of immunohistochemistry. Importantly, by responses pretreatment evaluated were tumor regardless expression RORX

with in advancing neuropathy. discuss safety Collectively, the therapy, meeting A event, trial the in inhibition to cut potentially due FDA the potential first-line PD-X year combination data discontinued approaches. peripheral the adverse treatment half to is of the treatment-related As data registrational only earlier anticipated X of March, in of which lines second support to in these setting. with was patient a

Moving our evalstatug ]. now CAB antibody, to CTLA-X [

of the of adverse survival tolerated, past evidence normal PD-X time, CTLA-X Over immune-related We to evalstatug limit blockade years, be increased [ the [ to lymph tolerability. CTLA-X We microenvironment receive approved at designed benefits. combination nodes. in events currently tissues evalstatug CTLA-X of oncologists clinical more avoid At that long-term blocking because CTLA-X tumor exposure doses in high ] in benefit acidic and will a shown relatively lines inhibition. patients drives believe the ] better enabling rate bind binding from with XX most antibodies same multiple clinical inhibition low prescribe have preferentially to healthy

announced of antibody. treatment combination X using patients X the responses XXX-milligram dose Last confirmed refractory for in quarter, we with PD-X

[ has ] drive of from dose benefit. to part another As increased update, higher XXX milligrams evidence clinical every given response was that patient XX whose today's additional been doses a melanoma milligrams in X providing achieved evalstatug weeks, now

patients continued mentioned, evaluating the dose dose are Jay escalation. are we As tolerating level presently part of that X-gram unprecedented our as a

continue We first-line flat melanoma cohorts non-small cancer the enroll dose. I combination lung and cell at in Phase to the XXX-milligram

are doses plans. a June use inhibitor on cancer will ASCO enthusiastic data and We refractory to registration highly Phase our readouts this higher report in are year. Investigators later we patients, for treatment X. Shifting to at a update CTLA-X additional I on at track

diagnosed We approximately for melanoma, marked melanoma. who unresectable are the newly half on now account patients metastatic patients or mutated unmet with BRAF focused of need among with

key by informed findings is strategy large prospective Our from trials. X clinical

BRAF patients inhibitors. should checkpoint treatment receive BRAF First, inhibitor before

of combined helps PD-X Second, blockade overall use CTLA-X survival. progression-free and and both drive

achieves patients. subgroup while inhibition binding Notably, can normal patient progression-free appeared these largely first of higher CTLA-X avoiding X overall survival the control CTLA-X believe tumor just CTLA-X for improve this that in melanoma tissues. inhibition survival. Third, BRAF quickly high our doses microenvironment improved specifically that months, for levels suggesting meaningfully We conditionally unprecedented safely CTLA-X and tumor at in blockade CTLA-X antibody achieve adding

by us over to to pivotal randomized designing on in few of ] [ positioning now are the mutated opportunities registrational an potentially a Sheri ] patients metastatic feedback initiate newly melanoma. [ like to FDA provide turn call unresectable evalstetub plus We the second We year, end. for pembrolizumab now anticipate Sheri? agents. BRAF I the trial, employing these this the to would for half efficient, with trial market year's diagnosed comments or blinded,

Sheri Lydick

Eric, success. The CAB to in There holds antibody CTLA-X, is of potential expected metastatic approximately many [ $X a ], [ to mutated that current evalsitab ]. everyone. has combined tremendous promise to billion size the immunotherapy first-line ] as metastatic approval market is effective. across evalsitab inhibitor with as inhibition you, potential afternoon, on indications but the BRAF by a present XXXX. therapeutic best-in-class I we PD-X our and [ of CTLA-X Based standard high status. Phase melanoma focused to often evolving patients melanoma approximately initially grow XX% and expand BRAF Continuing data, a billion opportunity regardless malignant the over likelihood be BRAF remains good to as are of efficient annually care for path be of and believe be can $XX immune mutations our worldwide to with tumors evalsitab solid is of checkpoint used on where Thank and continue are we potentially melanoma

potential with the documented earlier, avelstitab PD-X to the become in to inhibitor for combination patients. And standard benefits striking care anti-CTLA-X are has an of noted BRAF mutated PD-X Eric a [ clinical these the that As believe inhibitor ] particularly adding a of we patients. of

CAB-RORX-ADC, On to ozaritimad ]. our [ vedotin

clinical heavily clinical patients despite worldwide is recent first-line encouraged single for significant. need, grow for emerging $X limited to have remains mortality agent are size neck with on and to head have $X.X over are of profound The refractory particularly is treatment the advances, and next billion and is X worldwide approximately neck suboptimal patients that the head are there prevalence expected market profile cancer. this We progressed and and pretreated Therapies a cancer therapeutic And these current years. unmet rate significantly population options. for The billion who available in annually benefit. multi-refractory nearly

a head believe for Given could BioAtla. data neck and set ozoristimab the commercial cancer, we opportunity emerging [ ] vedotin encouraging in represent significant

also ] CAB-ADC for positioned We vedotin collaboration of this ozaritimab across a that solid well strategic the is expand potential [ indications. tumor will multiple believe

redefine standard the cancer we these believe the potentially potential I that, assets Given head mutated of like With back patients care Jay. would neck with turn of diseases. call to melanoma, with BioAtla to BRAF over for now indications and these and opportunities meaningful for value-creating the devastating to and combined represent prevalence

Jay Short

Thank you, Sheri.

on engager to EpCAM-CAB-CDX. achieve target CAB on surface optimal use the few ubiquitous the T-cell our our first-in-class technology of of requires a bispecific a words dual which safety. EpCAM Next, and cancer cells, is expressed CAB potentially selectivity antibody CAB

Phase potential the in II study to in from half Phase data full year. track this this report with on second set the study of the half are a also of second initiating We the year, I

The with our potentially has T-cell has neutropenia meeting is more carbohydrate This toxicity. reduce offers novel the others. a potential AACR associated tremendous with cancers patients new the pancreatic with last colon, broad potential in CAB-NectinX-ADC for annual recently off-target in We potential developed indications metastatic particular, and ADC has the CAB-NectinX-ADC. from of the risk data toxicity indicate at prostate, system BioAtla compelling and more next-gen PK including of CAB-enabled pancreas treatment for engager EpCAM treat and wide cancer. lung, that used antitumor space tumors, range reduced engager to our activity, for effective toxicology opportunity effective such a linker including presented breast, a therapies as among to month applicability, further T-cell

programs. today's our of focus the quarter to agent we to FDA I and for XXXX resources options the on evaluating that, Rick IND clearance review would have to call clinical first now we Rick? With as this our received part like several turn to update, financials. later-stage continue As are over

Richard Waldron

XXXX. ended of million our quarter prioritization $X.X Thank to IND Research for XX, $XX.X preclinical compared our to million programs March million clinical XXXX and were related was development XXXX. decrease the due same you, The to development $XX.X and Jay. of expenses in in for completion of NectinX quarter primarily the

XX, administrative $X.X decrease our the XXXX. quarter lower for March compensation ended stock-based trials data clinical in recently Cash ended and expect million XXXX, same expenses compared potentially compared XXXX, March fees. to was XX, same of primarily in were loss XXXX. to Net million to million trials net were The and cash enrollment continue near XXXX, our of as $XX.X $XX.X ADC a March $XXX.X in equivalents the in for compared March quarter to completed quarter to was professional million $XX.X for as expenses the $X.X for same registrational quarter XXXX. the activities to compared for XX, XXXX, R&D the used cash expected of decrease to ended operating term net million $XX.X loss We and $XX.X of in operating million to period activities the due XX, programs. General enable XX, used was million $X.X sets in quarter in the due cash for December XXXX. for million for Net to million

Our XXXX, quarter. approximately that $X annual occur the included cash in first ended during for payments March fiscal used typically XX, quarter our million

of cash expect We be cash And our ADC clinical the second allowing and XXXX, Jay. to XX, to equivalents for quarter of to half fund our XXXX. million into operating continue now treatment to year the complete the trials, half operations we June $XX as our burn in the approximately back second cash decrease and in current ending

Jay Short

Rick. you, Thank

date neck considerable CTLA-X turn in milestones your pipeline year, in operator with UPS RORX tumors. AXL the including to our meetings in take registrational FDA and to the our melanoma. registrational solid to With will We forward are remaining head pleased the look with with cancer, made we with results cumulative important on a portion our with for BRAF-mutated multiple have targeting discuss registrational guidance potentially that, several trial across We the trial to the of to and questions. potentially trial progress guidance we our it CAB planned back and this

Operator

first is Cheng [Operator Brian Instructions] question with Our from JPMorgan.

Lut Ming Cheng

confirmed head duration neck raw with mature? expectation as you're today? response responses on the what the on and seeing your And and elaborate you the ADC your the to of duration is data Can of set that

Jay Short

let I'll Brian. this Thanks, crack you. Eric take at Thank a one.

Eric Sievers

Brian. Thanks,

definitely were of and refer asked, treated a responses patients gives swimmers X then will to you effort, corporate question that on of we The of those the patients at addresses So after went confirmed And need follow-up but particularly -- Slide that will response, duration sense and days to I XX every our plot X our note that other the you week further estimate completing deck. were to then the were the updated the dosing. you I first. dosed employ we regimen.

follow-up the patients a XX. blue So bit for we have longer in on Slide

Jay Short

there's decreasing there add, are patients X also have just volume. confirm with X still that I'll treatment And are responses X of on the ongoing, which and that tumor could and

Lut Ming Cheng

also level? can today the And Great. maybe the the also of current response standard frame with response line then you in also duration us help line? and expectation care And of and of head neck in second third

Jay Short

you if look lines. fourth So the we're -- later mind, line when X prior plus we're line get here, I median lines, in the in -- keep think could at you thinking months a prior X X

response you really where on average. out look low, line bar on is from this there. So second exceptionally at The especially you're when is getting a standpoint, -- XX% rate

a see, think to like to encouraging. given would I line, see I it's the think, year late in, first X.X you Obviously, to there, like so go you'd I But you we're think lines months X And plus. plus.

Operator

from with Our Kelly Shi is next Jefferies. question

Dev Prasad

of on in recruiting Can Congratulations in on you Hi, questions on is of Dev you And need you do follow-up FDA on the stage expect it median second in also, you Shi. start early any everyone. I the with next color could for or progress. have a This that provide to Kelly might XXXX, couple before meet half? be the 'XX? AXL.

Jay Short

achieve occur which of -- each dosing is goal Yes, in multiple think should those of first second the half here we scans the for trial, we've the for because portion of we this potentially readily year. our registrational we're patients, that the intended completed main to

trial we data the get got thinking, assuming next start encouraging portion XXXX. current that to that to an would our -- of we continue encouraging registrational have so late of -- remaining opportunity And that portion in the

Dev Prasad

line? need line with more more the Or trial. or FDA? X lung second you on And randomized trial any third started non-small cancer, you alignment you III in Phase those whether do cell Can remind

Jay Short

X Well, lung recall I there. if correctly, the non-small cell median prior on cancer, lines of

reported year, that the of agnostic pretty look December So refractory extension we've to to it an last that target we at in out And patients. late, study was done and very patients.

in data -- appropriate pick data of end that to have we'll later that this we'll this get So to an way the we're quarter, going once still to quarter. give communicate and we

And into or line which so a -- we've how X if I our I then goes earlier than feedback line, and third comes think from is obviously already the on think proceed from there, to data we from. got -- second what FDA

strategy or to that out that feel data, final for positioned we'll lay be independently partners. we that, with So this final either with well

Operator

is with BTIG. Pohlman next Kaveri Our from question

Kaveri Pohlman

RORX-ADC any how received patients on pads from tell whether can us seen in physicians general? data? who you this ADC And in thinking head Also, line For or had as you're therapy, what and vedotin competitive any the other prior neck, about landscape [ feedback ]? Kita there were you of it's

Eric Sievers

Kaveri. Eric Thanks, answering. It's

we've a your also gotten from a USC, hear you review work. pleased to We just complete deck. response. was investigators which from at neck pleased progression was from treatment, [ were confirmed third exceptionally getting that's and So tolerability the of clinical patient serving They the some We many first, about they're anecdotes. these so challenging an therapies. feedback unmet fourth in physicians, this patients that need and as report having how I'll and second, is Sloan he on to enabling head go to response, to line that cancer, really in the felt where X the several patients spoke question and Kettering indicating Memorial our and about particularly emphasizing a it ], call of PI And and the received we that's corporate patient now back give the rapidity

did a other and/or treatment X asked about studies agent, platinum but prior ] prior many the patients regimen. When blocking that are anecdotes ADCs. of all And people certainly the question question a taxing of with [ the had then received received ongoing. you that to treatments, with look auristatin-based see interesting an I PD-X the or either had a ADCs, it's any prior received I didn't regard through

Sheri Lydick

question could existing competitive unmet within patients is there landscape. options. landscape, Sheri. remains profound a frontline competitive I on need in fail the this take the Obviously, who If Kaveri, the

is often [ XX%. know, in ] cetuximab an ORR, you As with second used line,

we So we look than and therapeutic future in at landscape, you action the to future different population development. an us that's within the profile really there the second-line that provides this are if pretreated think competitive mechanism think that have within of benefit the emerging the the the competitive existing as for remains even very in well need, unmet in patients landscape landscape. opportunity we those as a heavily And patient setting that existing

Kaveri Pohlman

I Got a AXL on for maybe this very guess RORX-ADC. And it. regimen. the is That's helpful. dosing both question and

just us any learned about studies, of You schedule thinking whether schedule tell regarding has Optimis? from significant these going you to and the been forward? are regimen what drug initial of saw the Can Project different XQXW. your PK/PD you you regimen a with profile from QXW for tell Is this this how differences dosing

Jay Short

-- I saying finish I'll start just off that just the to we this, X. I'll did us by use Phase remind all [indiscernible] in but XQXW say want

at. add Eric with this. new. certain But we've I'll certainly So what characteristics, XQXW not looked to to it's respect let It's that

Eric Sievers

Sure. Thanks, Jay.

of treatment as well for a And we're think, of instances other dosing, I So related few X deck our tolerated. where the discontinuation. I'll melanoma which to everyone leading X X-week week summarized refer AEs we've is XX that the exceptionally of to of every days are here, very Slide XQXW then both the I'll emphasize well. corporate and regimens, having cycle and

excellent is regimens. so And both tolerability with

see -- the We it intensive can rapid sense we are which is and the I more in data interesting red, is neck regimen seeing particular, in more disease first. of the patients patients, there that from spider study. and a on And longer XX in the get head plot a X weeks think did have there XX, patients the at -- with the that just of weeks control blue. you Slide those weeks we than that blue therapy, many, instances are because are X did And X passing the quite they passing on are many few exposure XX patients

well both I regimens and no So there. think tolerated, PK/PD, the surprises

good. looking So

Kaveri Pohlman

helpful. That's

Operator

Our with from Arthur question is He Wainright. H.C. next

Yu He

the data questions I neck. of on head a data. just in Congrats and and for neck had couple the the head

go for for So I on future gauging you here -- for first, line mentioned the these a in still second get discussion first. X the just your the [ to or so priority record with want I you half. first the to ] state depending want FDA

Eric Sievers

I Arthur. appreciate you, it. Thank

we're We or haven't both about a formal or target decision whether made going first to yet. second

like to to go agency vision designs Our trial is we'd both. for the and that discuss

first line, that or pair blockade. think remarkably For the ] [ the with statin-based well I ADCs PD-X

I alone. so excellent just really to we antibody platinum evaluation an it'd enable be PD-X a think in that. in the And I combination do Phase with of the PD-X antibody received that course, patients combination could, And first-line PD-X further with then

and second to Moving beyond.

Second of either we limited ] unmet or where number line, need, a monotherapy see would against an potentially cetuximab cetuximab chemotherapy [ enormous a and trial or straightforward there's [ beyond relatively compare design we possibly the approval then that data trial might an confirm for investigator and an endpoint endpoint choices with the the OS trial. PFS the review same enable with in and that ] would of accelerated early and

with that are So the exploring looking these agency. are possibilities the forward to we

Yu He

the helpful. the -- that expression to HPV the compared the with regarding have you any there? patients? I better looking response And Thanks Is -- the Eric, feel was has regarding into rate QXW. the HPV correlation marker just a I'm data, in the XQXW in very expression And these like there response curious,

Eric Sievers

Yes, a Arthur. question, great it's

aggressive recent that to can going that's seen It's patients very therapy receive expression. look continue not closely. we're therapy. to There's Those suggesting HPV some have data different. at the We with a deescalate little early a something they correlation bit

HPV investigators a correlations. our as obvious than seeing guided obvious think not right But seeing the to people the ask any by little add expression been not population. negative often And bit just RORX because of we're that's we've now, with question that a that I'll different so us. also them And correlations

we're so time. a this not diagnostic at And needing companion

Yu He

And you a for this quarter, patients for bit in program us the color may, could patients for the cycle XX receive Got I now, give cancer CTLA-X the the as type you. those little what's upcoming drug? monotherapy if the more as the data on well of medium number the for

Eric Sievers

Okay.

conditionally CTLA-X very So and We open relapsed/refractory moving to doors the binding you're carcinomas. asking about the melanomas the to and monotherapy. wide

would I the patients of different other clinical So broad cancer with weren't were diagnoses -- experience. trials -- different in that a anticipate eligible that X very for single number monotherapy unusual participating sometimes

Our that overall XXX with clearly today, happy milligrams. XXX we patient also to was and level. I'm profile the treated the the And safety characterize at the both third say X-gram to monotherapy goal dosing at

XX-kilo level XX.X of now is kilogram per high dose X very at on which the we've a gram, all X individuals infused the milligrams of adult. based So

looking these to ASCO then that just the presentation subsequent describe outcome of we're a So forward and you've June X monotherapy about. patients to asked the presentation on

Yu He

Thanks, Great. Thanks taking for question. Eric. our

Operator

question EFHud ]. next Tony with [ is from Butler Our

Unknown Analyst

part moving will before of part -- end other I than the question, some have sufficiently of again, have That's mutated -- make in is anticipate with if combination a And just I'm to And does could choice melanoma arm, you more be, then simply X judgments been X comparator previous I Pembro -- gram will physician's or like about if from be decision with this be do you I [ the this forward front I'd go apparently is in may. Yes. one. may. agents Will [ that duration And follow-up, CTLA-X. Part the utilized X study? BRAF Pembro have up curious, ] sufficient that ]. may assume making you that being you're that I other And there types the back there at line? to A,

Eric Sievers

in sequence. take I So why these don't

So very sufficient question we will. is believe the asked have we you follow-up, first will and we

to to dosing presently, that we patients dose -- experience gain regard diagnosed additional level. unresectable So without this I it want And melanoma. to currently or newly metastatic affirm are mutation, melanoma, with BRAF at

So these to lead I to then Because then want emphasize is are trial. patients. first-line the that. that going into proposed just pivotal

metastatic want X question be second [ melanoma, newly agency and I are they ]. both as necessary to remind strategies that combination nivolumab ] [ opto unresectable everyone plus interesting is a or that really Your that of there diagnosed could will include for employed and one, of [ think the feedback be pembrolizumab lag here. I ipilimumab monotherapy, nivolumab ], those or

comparator that And so is pembrolizumab ] frontline our notable pembrolizumab And presently because randomized as opportunity. arm [ melanoma other several like vision trials. a that labeled their against we'd a sponsors it's the are study in to blinded, represents run it currently using [ ] monotherapy

Unknown Analyst

-- the on the the linker. the commentary. for follow-up carbohydrate follow NectinX My ADC question up you or thank with Eric, is

that that's antibody? door is the if the which of for most add does to linker optimal the no, payload you mechanistically, number carbohydrate you And the what NectinX-ADC? Is question payload today? can fine, Just the actually is, the the but limit the say

Jay Short

[Indiscernible]. us I'll allows to design Basically, above that increase the DARX one, carbohydrate linker actual take system the ]. the of [

So actually, because a it's going reduce we it's very we've [ the to ]. profile talks. safety going We current increase NectinX think help DARX. profile. to safety And us ADC is to add good DARX off-target the to the above And seen

further CAB, talk. reduces also addition, In so a on-target it's

together. these X pieces really bringing we're So

because to compound, specific a toxicities the and is way in And as have Nectin-X, a marketed is various known rash. very X significant of those

able drug because part that allow animal and know together. to for to data also eliminate is been we our index to the had that kind data -- enable -- see therapeutic X not of totally activity, And CAB pancreatic should excited we're rash and from least in suggest We're linker working of have Nectin-X that at that have do linked we ability this we've this modeling so not noticed a we'll cancer. just reduce, And to is the observation further. we've targets and the to able the to linker if about and we carbohydrate the those additional associated and us carbohydrate with be traditionally

in -- at is RORX this, carbohydrate AXL However, I the specific I the to is toxicity emphasize way, had think, this a of all saying we've better saying and what Nectin-X. very is seen because don't want we peptide resolve linker that to and a linker that than we no

RORX toxicities We those of and drugs. safe are very kind with our AXL seeing profile without

So to I a toxicity. clearly purpose think address specific defined in into this with a way, a we very program very came

so in with I'll bar a X because chance go this low an a that get dosing. nice safety And should I these you just there's about a think quickly combination, into go drug of allow is very quite that results to thing known you to add, wide. here it have potentially And with could level very indication

to with And validate should you your your really I, so learn safety this both adequate Phase efficacy and compound.

So an exciting asset.

Unknown Analyst

Thanks fantastic. it's Jay, very much.

Operator

CEO, the over comments. Thank at time. Short, to back like closing you. no hand to Jay I'd questions for There are this further floor

Jay Short

are a everyone, and by precipice our interest very market. of you, for being to We're to lot BioAtla. in on are your that Thank continued hopeful obviously data and able and attendance I of think drugs today bring encouraged the very

for you So hopefully, your thank continues and it attention.

Operator

concludes conference. today's This

may Thank disconnect time. this at You your your participation. for lines you

BioAtla (BCAB) 14 May 242024 Q1 Earnings call transcript